Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

Cancer Treatment

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

The decision follows PALOMA‑3 data demonstrating pharmacokinetic noninferiority plus sharply fewer administration reactions.

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma